Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8382516 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1MCHR1F2PRSS1 | |
| SCHEMBL8789808 | 0.84 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1F2PRSS1PRSS2 | |
| SCHEMBL8792482 | 0.81 | TDP1 (0.47) | SMN1; SMN2ALDH1A1LMNAHTTTSHR | |
| SCHEMBL9775628 | 0.80 | GAA (0.46) | SMN1; SMN2ALDH1A1F2PRSS1PRSS2 | |
| SCHEMBL8789462 | 0.79 | F2 (0.49) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5886057 | 0.76 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1F2PRSS1PRSS2 | |
| SCHEMBL3234699 | 0.75 | TDP1 (0.49) | SMN1; SMN2ALDH1A1LMNANPSR1HTT | |
| SCHEMBL9078382 | 0.73 | TSHR (0.55) | LMNARECQLGAATSHR | |
| SCHEMBL6153961 | 0.72 | L3MBTL1 (0.50) | SMN1; SMN2ALDH1A1F2PRSS1PRSS2 | |
| Hexane SCHEMBL11658743 | 0.71 | MCHR1 (0.53) | SMN1; SMN2ALDH1A1MCHR1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344515-B9 | METHOD AND INTERMEDIATES FOR PREPARING 2-ALKOXY AND 2-ARYLOXY ESTROGEN COMPOUNDS | NAXOSPHARMA S R L (IT) | 2013-06-26 | — | — | EP | disclosed |
| EP-2344515-B1 | METHOD AND INTERMEDIATES FOR PREPARING 2-ALKOXY AND 2-ARYLOXY ESTROGEN COMPOUNDS | NAXOSPHARMA S R L (IT) | 2013-02-13 | — | — | EP | disclosed |
| EP-2344515-A1 | METHOD AND INTERMEDIATES FOR PREPARING 2-ALKOXY AND 2-ARYLOXY ESTROGEN COMPOUNDS | Naxospharma S.R.L. (IT) | 2011-07-20 | — | — | EP | disclosed |
| US-20110130581-A1 | Method and intermediates for preparing 2-alkoxy and 2-aryloxy estrogen compounds | NAXOSPHARMA S.R.L. | 2011-06-02 | — | — | US | disclosed |
| US-7901904-B2 | Method and intermediates for preparing 2-alkoxy and 2-aryloxy estrogen compounds | NAXOSPHARMA S.R.L. (IT) | 2011-03-08 | — | — | US | disclosed |
| US-20100099141-A1 | Method and intermediates for preparing 2-alkoxy and 2-aryloxy estrogen compounds | NAXOSPHARMA S.R.L. | 2010-04-22 | — | — | US | disclosed |
| WO-2010043506-A1 | METHOD AND INTERMEDIATES FOR PREPARING 2-ALKOXY AND 2-ARYLOXY ESTROGEN COMPOUNDS | NAXOSPHARMA S.R.L. (IT) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130581-A1 | Method and intermediates for preparing 2-alkoxy and 2-aryloxy estrogen compounds | CYP19A1, HSD17B11, ESR1 | SMN1; SMN2 4708/4885ALDH1A1 257/4885MCHR1 1316/4885 |
| US-20100099141-A1 | Method and intermediates for preparing 2-alkoxy and 2-aryloxy estrogen compounds | CYP19A1, HSD17B11, ESR1 | SMN1; SMN2 4680/4885ALDH1A1 267/4885MCHR1 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.